- Home
- LPA vs ENGN Comparison
LPA vs ENGN Comparison
Compare LPA & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPA
- ENGN
- Stock Information
- Founded
- LPA 2013
- ENGN 1999
- Country
- LPA United States
- ENGN Canada
- Employees
- LPA N/A
- ENGN N/A
- Industry
- LPA
- ENGN
- Sector
- LPA
- ENGN
- Exchange
- LPA Nasdaq
- ENGN Nasdaq
- Market Cap
- LPA 310.7M
- ENGN 297.7M
- IPO Year
- LPA N/A
- ENGN N/A
- Fundamental
- Price
- LPA $8.86
- ENGN $4.33
- Analyst Decision
- LPA
- ENGN Buy
- Analyst Count
- LPA 0
- ENGN 9
- Target Price
- LPA N/A
- ENGN $25.22
- AVG Volume (30 Days)
- LPA 10.8K
- ENGN 28.7K
- Earning Date
- LPA 05-14-2025
- ENGN 03-10-2025
- Dividend Yield
- LPA N/A
- ENGN N/A
- EPS Growth
- LPA N/A
- ENGN N/A
- EPS
- LPA N/A
- ENGN N/A
- Revenue
- LPA $44,311,428.00
- ENGN N/A
- Revenue This Year
- LPA N/A
- ENGN N/A
- Revenue Next Year
- LPA N/A
- ENGN N/A
- P/E Ratio
- LPA N/A
- ENGN N/A
- Revenue Growth
- LPA 22.46
- ENGN N/A
- 52 Week Low
- LPA $6.00
- ENGN $4.00
- 52 Week High
- LPA $525.00
- ENGN $17.10
- Technical
- Relative Strength Index (RSI)
- LPA N/A
- ENGN 33.72
- Support Level
- LPA N/A
- ENGN $4.22
- Resistance Level
- LPA N/A
- ENGN $5.00
- Average True Range (ATR)
- LPA 0.00
- ENGN 0.47
- MACD
- LPA 0.00
- ENGN -0.04
- Stochastic Oscillator
- LPA 0.00
- ENGN 20.62
About LPA Logistic Properties of the Americas
Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns and manages a diversified portfolio of warehouse logistics assets in Central America and the South America. It focuses on modern Class A logistics real estate in high growth and high barrier-to-entry markets that are undersupplied and have low penetration rates.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.